Efficacy of Assistive Soft Gloves in Chronic Stroke Rehabilitation (NCT07327151) | Clinical Trial Compass
CompletedNot Applicable
Efficacy of Assistive Soft Gloves in Chronic Stroke Rehabilitation
Turkey (Türkiye)34 participantsStarted 2024-02-01
Plain-language summary
Stroke is a leading cause of disability, with hemiparesis affecting approximately 85% of survivors, particularly affecting the upper limbs, which play a critical role in the activities of daily living (ADLs). While robot-assisted rehabilitation (RAR) is gaining increasing attention owing to its capacity for intensive, repetitive, and task-specific training that promotes neuroplasticity, robot-assisted hand rehabilitation (RAHR) is not yet part of standard protocols and is understudied. This study investigated the effects of a soft rehabilitation glove (SRG) applied in addition to traditional neurorehabilitation on upper limb motor function and ADLs in individuals with chronic stroke.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Individuals aged 18 and above who have experienced cerebrovascular events confirmed by neuroimaging and are planned to be enrolled in a neurological rehabilitation treatment program.
. Those whose event date was more than 3 (three) months.
. Individuals with upper limb and hand assessment of 3 or above according to the Brunnstrom Motor Assessment Scale.
. Those with spasticity level of 2 and below in upper limb muscle groups according the Modified Ashworth Scale.
. Individuals scoring 24 and above on the Standardized Mini-Mental Test.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Goal Assessment Scale (GAS)-Light
Timeframe: Post-treatment (at the end of the 3 th week)
2
Modified Frenchay Scale (MFS)
Timeframe: Pre-treatment and Post-treatment (at the end of 3th week)
3
Jebsen Taylor Hand Function Test
Timeframe: Pre-treatment and Post-treatment (at the end of 3th week)
. Those with severe soft tissue and/or joint contractures in the upper limbs.
. Individuals with active reflex sympathetic dystrophy, active arthritis, fractures, circulatory disorders, or bone malignancies in the affected upper limbs.
. Those with peripheral nerve injuries in the affected upper limb.
. Individuals with cognitive or behavioral disorders that would hinder participation in the treatment program.
. Those with aphasia and apraxia at a level that would hinder participation in the treatment program.